2L9 Intrinsic Valuation and Fundamental Analysis - Blueprint Medicines Corp

Watchlist Manager

Watchlist

Price: 110.05 EUR

Market Cap: €6.9B

B	Blueprint Medicines Corp F:2L9	US
M	MPJ Logistics PCL SET:MPJ	TH
B	Becton Dickinson and Co SWB:BOX	US
P	Pandora A/S F:3P7	DK
	Odfjell SE F:O7F	NO
B	Brinks Co F:PTY	US
L	LTMH PCL SET:LTMH	TH
M	Mclaren Resources Inc F:3ML	CA
	Red Cat Holdings Inc F:BQ73	PR
S	Softlab SpA XMUN:OT3	IT
N	Newpath Resources Inc CNSX:PATH	CA
E	Estee Lauder Companies Inc DUS:ELAA	US
C	CMO PCL SET:CMO	TH
	Newlox Gold Ventures Corp F:NGO	CA
	Vertiv Holdings Co NYSE:VRT	US
	Orsted A/S CSE:ORSTED	DK
G	Grupo Financiero Galicia SA F:GF4	AR
K	Kingsmen CMTI PCL SET:K	TH
M	Montego Resources Inc F:4MO	CA
	EchoStar Corp NASDAQ:ECHO	US

Intrinsic Value

Is 2L9 undervalued or overvalued?

See the intrinsic value estimate for Blueprint Medicines Corp and find out whether today’s valuation is cheap or expensive by its own historical standards.

Do our valuations actually work? See backtest results .

2L9 Intrinsic Value

Unlock

Today vs. history

See how today’s valuation compares with 2L9’s past valuations and how the stock performed after similar periods.

See what happened next Free account required

Track Buy Zone

20% below Intrinsic Value

Get notified when the price drops into your buy zone

Current Price €110.05

Intrinsic Value Locked

Margin of Safety 20% Locked

Or choose another margin of safety

0% below Intrinsic Value

10% below Intrinsic Value

30% below Intrinsic Value

40% below Intrinsic Value

50% below Intrinsic Value

Custom

Fundamental Analysis

What Blueprint Medicines Does

Biotechnology Health Care

In the demanding world of biotechnology, Blueprint Medicines Corp stands out as an influential player, steering the course of precision therapy through innovation. Founded by a team of forward-thinking scientists, the company is deeply entrenched in the pursuit of novel treatments targeting rare genetic diseases and cancers driven by specific genomic alterations. Leveraging its proprietary compound library and a research-centric approach, Blueprint Medicines develops small-molecule kinase inhibitors designed to selectively modulate growth and survival signals in cells.

Headquarters: United States of America US
Employees: 495
IPO date: Apr 30, 2015

Read the full company overview

How Blueprint Medicines makes money

The financial backbone of Blueprint Medicines is built upon a well-rounded strategy encompassing both in-house drug development and strategic collaborations. As the company shepherds its proprietary drugs through the rigorous phases of clinical trials, it also engages in valuable partnerships with pharmaceutical giants to bolster its research capabilities and market reach. With approval and commercialization of therapies like Ayvakit for certain forms of gastrointestinal stromal tumors, Blueprint Medicines generates substantial revenue. These gains are further compounded by milestone payments and royalties from collaborations, all while maintaining a robust pipeline to ensure continued innovation and future income streams. In this way, Blueprint marries scientific rigor with strategic acumen, carving out a sustainable and impactful presence in the biopharmaceutical landscape.

View Company Overview